Latent Tuberculosis Infection

Latent tuberculosis infection (LTBI) is a clinical condition characterized by a positive tuberculin skin test in the absence of clinical or radiological signs of active tuberculosis disease. It has been estimated that one third of the world's population is latently infected with Mycobacterium tuberculosis and serves as an enormous reservoir for future cases of active tuberculosis. The detection and treatment of individuals with LTBI and a high risk of progression to active tuberculosis are effective means to control the spread of tuberculosis. Furthermore, a better understanding of the host-pathogen interactions that result in latent infection could provide important insights for future drug or vaccine development. This chapter reviews recent developments in the molecular genetics, natural history, diagnosis, and treatment of LTBI within its historical context, including the impact of human immunodeficiency virus infection. Current treatment recommendations are also summarized.

KEYWORDS

Tuberculosis - latency - preventive therapy - dual TB + HIV infection

REFERENCES

• 1 Tufariello J M, Chan J, Flynn J L. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection.  Lancet Infect Dis. 2003;  3 578-590
• 2 Corbett E L, Watt C J, Walker N et al.. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.  Arch Intern Med. 2003;  163 1009-1021
• 3 Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country.  JAMA. 1999;  282 677-686
• 4 Styblo K, Meijer J, Sutherland I. The transmission of tubercle bacilli: its trend in a human population.  Bull World Health Organ. 1969;  41 137-178
• 5 Enarson D A, Rouillon A. The epidemiological basis of tuberculosis control. In: Davis PDO Clinical Tuberculosis. London; Chapman & Hall 1994: 19-32
• 6 Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli.  Adv Tuberc Res. 1976;  19 1-63
• 7 Selwyn P A, Hartel D, Lewis V A et al.. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.  N Engl J Med. 1989;  320 545-550
• 8 Manabe Y C, Bishai W R. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting.  Nat Med. 2000;  6 1327-1329
• 9 Russell D G. Mycobacterium tuberculosis: here today, and here tomorrow.  Nat Rev Mol Cell Biol. 2001;  2 569-577
• 10 Betts J C, Lukey P T, Robb L C, McAdam R A, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling.  Mol Microbiol. 2002;  43 717-731
• 11 Wayne L G, Sohaskey C D. Nonreplicating persistence of Mycobacterium tuberculosis .  Annu Rev Microbiol. 2001;  55 139-163
• 12 Yuan Y, Crane D D, Barry C E. 3. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog.  J Bacteriol. 1996;  178 4484-4492
• 13 Boon C, Li R, Qi R, Dick T. Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model.  J Bacteriol. 2001;  183 2672-2676
• 14 Sherman D R, Voskuil M, Schnappinger D, Liao R, Harrell M I, Schoolnik G K. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin.  Proc Natl Acad Sci USA. 2001;  98 7534-7539
• 15 Cunningham A F, Spreadbury C L. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog.  J Bacteriol. 1998;  180 801-808
• 16 Yuan Y, Crane D D, Simpson R M et al.. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages.  Proc Natl Acad Sci USA. 1998;  95 9578-9583
• 17 DeMaio J, Zhang Y, Ko C, Young D B, Bishai W R. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis .  Proc Natl Acad Sci USA. 1996;  93 2790-2794
• 18 Chen P, Ruiz R E, Li Q, Silver R F, Bishai W R. Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF.  Infect Immun. 2000;  68 5575-5580
• 19 Geiman D E, Kaushal D, Ko C et al.. Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis.  Infect Immun. 2004;  , In press
• 20 Wayne L G. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions.  Am Rev Respir Dis. 1976;  114 807-811
• 21 Wayne L G, Hayes L G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.  Infect Immun. 1996;  64 2062-2069
• 22 Wayne L G, Lin K Y. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions.  Infect Immun. 1982;  37 1042-1049
• 23 Boon C, Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy.  J Bacteriol. 2002;  184 6760-6767
• 24 Park H D, Guinn K M, Harrell M I et al.. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis .  Mol Microbiol. 2003;  48 833-843
• 25 Florczyk M A, McCue L A, Purkayastha A, Currenti E, Wolin M J, McDonough K A. A family of acr-coregulated Mycobacterium tuberculosis genes shares a common DNA motif and requires Rv3133c (dosR or devR) for expression.  Infect Immun. 2003;  71 5332-5343
• 26 Voskuil M I, Schnapppinger D, Visconti K C et al.. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program.  J Exp Med. 2003;  198 705-713
• 27 Shi L, Jung Y J, Tyagi S, Gennaro M L, North R J. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence.  Proc Natl Acad Sci USA. 2003;  100 241-246
• 28 Hingley-Wilson S M, Sambandamurthy V K, Jacobs Jr W R. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis .  Nat Immunol. 2003;  4 949-955
• 29 McKinney J D, Honer zu Bentrup K, Munoz-Elias E J et al.. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.  Nature. 2000;  406 735-8
• 30 Dahl J L, Kraus C N, Boshoff H I et al.. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice.  Proc Natl Acad Sci USA. 2003;  100 10026-10031
• 31 Johansen K A, Gill R E, Vasil M L. Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria.  Infect Immun. 1996;  64 3259-3266
• 32 Ando M, Yoshimatsu T, Ko C, Converse P J, Bishai W R. Deletion of Mycobacterium tuberculosis sigma factor E results in delayed time to death with bacterial persistence in lungs of aerosol-infected mice.  Infect Immun. 2003;  , In press
• 33 Kaushal D, Schroeder B G, Tyagi S et al.. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH.  Proc Natl Acad Sci USA. 2002;  99 8330-8335
• 34 Sun R, Converse P J, Ko C, Tyagi S, Morrison N E, Bishai W R. Mycobacterium tuberculosis sigC is an ECF sigma factor required for lethality in mice and for the conditional expression of a defined set of genes.  Mol Microbiol. 2004;  52 25-38
• 35 Steyn A J, Collins D M, Hondalus M K, Jacobs Jr W R, Kawakami R P, Bloom B R. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth.  Proc Natl Acad Sci USA. 2002;  99 3147-3152
• 36 Lewis K N, Liao R, Guinn K M et al.. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation.  J Infect Dis. 2003;  187 117-123
• 37 Boshoff H IM, Reed M B, Barry III C E, Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis .  Cell. 2003;  113 183-193
• 38 Loudon R G, Williamson J, Johnson J M. An analysis of 3,485 tuberculosis contacts in the city of Edinburgh during 1954-1955.  Am Rev Tuberc. 1958;  77 623-643
• 39 Nardell E A, Piessens W F. Transmission of tuberculosis. In: Reichman LB, Hershfield ES Tuberculosis: A Comprehensive International Approach. 2nd ed. New York; Marcel Dekker 2000: 215-240
• 40 Koch R. Die Atiologie der Tuberkulose.  Berl Klin Wochenschr. 1882;  19 221-230
• 41 Behr M A, Warren S A, Salamon H et al.. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli.  Lancet. 1999;  353 444-449
• 42 Loudon R G, Bumgarner L R, Lacy J, Coffman G K. Aerial transmission of mycobacteria.  Am Rev Respir Dis. 1969;  100 165-171
• 43 Wells W. On airborne infection, II: Droplets and droplet nuclei.  Am J Hyg. 1934;  20 611-618
• 44 Shaw J B, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status.  Am Rev Tuberc. 1954;  69 724-732
• 45 Grzybowski S, Barnett G D, Styblo K. Contacts of cases of active pulmonary tuberculosis.  Bull Int Union Tuberc. 1975;  50 90-106
• 46 van Geuns H A, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969.  Bull Int Union Tuberc. 1975;  50 107-121
• 47 Comstock G W. Epidemiology of tuberculosis. In: Reichman LB, Hershfield ES Tuberculosis: A Comprehensive International Approach. 2nd ed. New York; Marcel Dekker 2000: 129-156
• 48 Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle.  Tuberc Lung Dis. 1992;  73 73-76
• 49 Houk V N, Baker J H, Sorensen K, Kent D C. The epidemiology of tuberculosis infection in a closed environment.  Arch Environ Health. 1968;  16 26-35
• 50 Dickinson J M, Lefford M J, Lloyd J, Mitchison D A. The virulence in the guinea-pig of tubercle bacilli from patients with pulmonary tuberculosis in Hong Kong.  Tubercle. 1963;  44 446-451
• 51 Middlebrook G, Cohn M L. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.  Science. 1953;  118 297-299
• 52 Pym A S, Saint-Joanis B, Cole S T. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans.  Infect Immun. 2002;  70 4955-4960
• 53 Narain R, Naganna K, Murthy S S. Incidence of pulmonary tuberculosis.  Am Rev Respir Dis. 1973;  107 992-1001
• 54 Barnes P F, Cave M D. Molecular epidemiology of tuberculosis.  N Engl J Med. 2003;  349 1149-1156
• 55 O'Grady F, Riley R L. Experimental airborne tuberculosis.  Adv Tuberc Res. 1963;  12 150-190
• 56 Valway S E, Sanchez M P, Shinnick T F et al.. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis .  N Engl J Med. 1998;  338 633-639
• 57 Sutherland I. The ten-year incidence of clinical tuberculosis following “conversion” in 2550 individuals aged 14 to 19 years. The Hague; KNCV 1968 TSTRU Progress Report
• 58 Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: a general review.  Adv Tuberc Res. 1969;  17 28-106
• 59 Chiba Y, Kurihara T. Development of pulmonary tuberculosis with special reference to the time interval after tuberculin conversion.  Bull Int Union Tuberc. 1979;  54 263-264
• 60 Styblo K, Sutherland I. Epidemiology of tuberculosis in the child.  Bull Int Union Tuberc. 1982;  57 134-141
• 61 Canetti G. The Tubercle Bacillus in the Pulmonary Lesions Of Man. New York; Springer 1955
• 62 Rieder H L, Cauthen G M, Comstock G W, Snider Jr D E. Epidemiology of tuberculosis in the United States.  Epidemiol Rev. 1989;  11 79-98
• 63 Hopewell P C, Chaisson R E. Tuberculosis and human immunodeficiency virus infection. In: Reichman LB, Hershfield ES Tuberculosis: A Comprehensive International Approach. 2nd ed. New York; Marcel Dekker 2000: 525-552
• 64 Cohn D L, El-Sadr W. Treatment of latent tuberculosis infection. In: Reichman LB and Hershfield ES Tuberculosis: A Comprehensive International Approach. 2nd ed. New York; Marcel Dekker 2000: 471-502
• 65 Bucher H C, Griffith L E, Guyatt G H et al.. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.  AIDS. 1999;  13 501-507
• 66 Girardi E, Antonucci G, Vanacore P et al.. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection.  AIDS. 2000;  14 1985-1991
• 67 Centers for Disease Control and Prevention . Tuberculosis outbreak among persons in a residential facility for HIV-infected persons-San Francisco.  MMWR Morb Mortal Wkly Rep. 1991;  40 649-652
• 68 Daley C L, Small P M, Schecter G F et al.. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms.  N Engl J Med. 1992;  326 231-235
• 69 Dooley S W, Villarino M E, Lawrence M et al.. Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients.  JAMA. 1992;  267 2632-2634
• 70 Di Perri G, Cruciani M, Danzi M C et al.. Nosocomial epidemic of active tuberculosis among HIV-infected patients.  Lancet. 1989;  2 1502-1504
• 71 American Thoracic Society . Treatment of tuberculosis and other mycobacterial diseases.  Am Rev Respir Dis. 1983;  127 790-796
• 72 Jones J L, Hanson D L, Dworkin M S, DeCock K M. HIV-associated tuberculosis in the era of highly active antiretroviral therapy.  Int J Tuberc Lung Dis. 2000;  4 1026-1031
• 73 Selwyn P A, Sckell B M, Alcabes P, Friedland G H, Klein R S, Schoenbaum E E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.  JAMA. 1992;  268 504-509
• 74 Centers for Disease Control and Prevention/American Thoracic Society . Targeted tuberculin testing and treatment of latent tuberculosis infection.  MMWR Morb Mortal Wkly Rep. 2000;  49 1-51
• 75 van Soolingen D, Borgdorff M W, de Haas P E et al.. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997.  J Infect Dis. 1999;  180 726-736
• 76 Burgos M, DeRiemer K, Small P M, Hopewell P C, Daley C L. Relative fitness of drug-resistant and drug-susceptible strains of Mycobacterium tuberculosis in San Francisco.  Am J Respir Crit Care Med. 2003;  165(suppl 8) A18
• 77 Garcia-Garcia M L, Ponce D L, Jimenez-Corona M E et al.. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico.  Arch Intern Med. 2000;  160 630-636
• 78 Godfrey-Faussett P, Sonnenberg P, Shearer S C et al.. Tuberculosis control and molecular epidemiology in a South African gold-mining community.  Lancet. 2000;  356 1066-1071
• 79 Frieden T R, Sherman L F, Maw K L et al.. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes.  JAMA. 1996;  276 1229-1235
• 80 Kruuner A, Hoffner S E, Sillastu H et al.. Spread of drug-resistant pulmonary tuberculosis in Estonia.  J Clin Microbiol. 2001;  39 3339-3345
• 81 Horwitz O, Comstock G W. What is a case of tuberculosis? The tuberculosis case spectrum in eight countries evaluated from 1235 case histories and roentgenograms.  Int J Epidemiol. 1973;  2 145-152
• 82 Alland D, Kalkut G E, Moss A R et al.. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods.  N Engl J Med. 1994;  330 1710-1716
• 83 Small P M, Hopewell P C, Singh S P et al.. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods.  N Engl J Med. 1994;  330 1703-1709
• 84 Ferebee S H, Palmer C E. Prevention of experimental tuberculosis with isoniazid.  Am Rev Tuberc. 1956;  73 1-18
• 85 Ferebee S H, Hopwood L, Palmer C E. Studies on prevention of experimental tuberculosis with isoniazid, II: Effects of different dosage regimens.  Am Rev Tuberc. 1956;  74 917-939
• 86 Runyon E H. Preventive treatment in tuberculosis: a statement by the committee on therapy, American Thoracic Society.  Am Rev Respir Dis. 1965;  91 297-298
• 87 International Union Against Tuberculosis . Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.  Bull World Health Organ. 1982;  60 555-564
• 88 Comstock G W, Baum C, Snider Jr D E. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.  Am Rev Respir Dis. 1979;  119 827-830
• 89 Gordin F M, Matts J P, Miller C et al.. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis.  N Engl J Med. 1997;  337 315-320
• 90 Hawken M P, Meme H K, Elliott L C et al.. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.  AIDS. 1997;  11 875-882
• 91 Mwinga A, Hosp M, Godfrey-Faussett P et al.. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.  AIDS. 1998;  12 2447-2457
• 92 Pape J W, Jean S S, Ho J L, Hafner A, Johnson Jr W D. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.  Lancet. 1993;  342 268-272
• 93 Whalen C C, Johnson J L, Okwera A et al.. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus.  N Engl J Med. 1997;  337 801-808
• 94 Johnson J L, Okwera A, Hom D L et al.. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.  AIDS. 2001;  15 2137-2147
• 95 Quigley M A, Mwinga A, Hosp M et al.. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.  AIDS. 2001;  15 215-222
• 96 Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?.  Int J Tuberc Lung Dis. 1999;  3 847-850
• 97 Ferebee S H, Mount F W. Antituberculosis chemoprophylaxis with isoniazid.  Am Rev Respir Dis. 1963;  87 453-454
• 98 Garibaldi R A, Drusin R E, Ferebee S H, Gregg M B. Isoniazid-associated hepatitis: report of an outbreak.  Am Rev Respir Dis. 1972;  106 357-365
• 99 Kopanoff D E, Snider Jr D E, Caras G J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.  Am Rev Respir Dis. 1978;  117 991-1001
• 100 American Thoracic Society . Preventive therapy of tuberculous infection.  Am Rev Respir Dis. 1974;  110 371-374
• 101 Mehta J B, Dutt A K, Harvill L, Henry W. Isoniazid preventive therapy for tuberculosis: are we losing our enthusiasm?.  Chest. 1988;  94 138-141
• 102 Mitchell J R, Zimmerman H J, Ishak K G et al.. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.  Ann Intern Med. 1976;  84 181-192
• 103 Scharer L, Smith J P. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.  Ann Intern Med. 1969;  71 1113-1120
• 104 Moulding T S, Redeker A G, Kanel G C. Twenty isoniazid-associated deaths in one state.  Am Rev Respir Dis. 1989;  140 700-705
• 105 Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.  JAMA. 1999;  281 1014-1018
• 106 Salpeter S R, Sanders G D, Salpeter E E, Owens D K. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.  Ann Intern Med. 1997;  127 1051-1061
• 107 Snider Jr D E, Caras G J. Isoniazid-associated hepatitis deaths: a review of available information.  Am Rev Respir Dis. 1992;  145 494-497
• 108 Oestreicher R, Dressler S H, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid.  Am Rev Tuberc. 1954;  70 504-508
• 109 Snider D E. Pyridoxine supplementation during isoniazid therapy.  Tubercle. 1980;  61 191-196
• 110 Gourevitch M N, Alcabes P, Wasserman W C, Arno P S. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.  Int J Tuberc Lung Dis. 1998;  2 531-540
• 111 Hong Kong Chest Service/Tuberculosis Research Centre MBMRC . A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong.  Am Rev Respir Dis. 1992;  145 36-41
• 112 Lecoeur H F, Truffot-Pernot C, Grosset J H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.  Am Rev Respir Dis. 1989;  140 1189-1193
• 113 Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.  Antimicrob Agents Chemother. 1992;  36 548-551
• 114 Fox W. Drug combinations and the bioavailability of rifampicin.  Tubercle. 1990;  71 241-245
• 115 Dhillon J, Dickinson J M, Sole K, Mitchison D A. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.  Antimicrob Agents Chemother. 1996;  40 552-555
• 116 Gordin F, Chaisson R E, Matts J P et al.. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial.  JAMA. 2000;  283 1445-1450
• 117 Halsey N A, Coberly J S, Desormeaux J et al.. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.  Lancet. 1998;  351 786-792
• 118 Ormerod L P. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis.  Arch Dis Child. 1998;  78 169-171
• 119 Joint Tuberculosis Committee of the British Thoracic Society . Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998.  Thorax. 1998;  53 536-548
• 120 Polesky A, Farber H W, Gottlieb D J et al.. Rifampin preventive therapy for tuberculosis in Boston's homeless.  Am J Respir Crit Care Med. 1996;  154 1473-1477
• 121 Villarino M E, Ridzon R, Weismuller P C et al.. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.  Am J Respir Crit Care Med. 1997;  155 1735-1738
• 122 Grosset J, Leventis S. Adverse effects of rifampin.  Rev Infect Dis. 1983;  5(suppl 3) S440-S450
• 123 Campagna M, Calix A, Hauser G. Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study.  Am Rev Tuberc. 1954;  69 334-350
• 124 McDermott W, Ormond L, Muschenheim C, Deuschle K, McCune Jr R M, Tompsett R. Pyrazinamide-isoniazid in tuberculosis.  Am Rev Tuberc. 1954;  69 319-333
• 125 Centers for Disease Control and Prevention . Management of persons exposed to multidrug-resistant tuberculosis.  MMWR Morb Mortal Wkly Rep. 1992;  41 61-71
• 126 Geiter L J. Preventive therapy of tuberculosis. In: Gangadharam PRJ, Jenkins PA Mycobacteria, Vol 2: Chemotherapy. New York; Chapman & Hall 1998: 297-312
• 127 Centers for Disease Control and Prevention . Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003.  MMWR Morb Mortal Wkly Rep. 2003;  52 735-739
• 128 Combs D L, O'Brien R J, Geiter L J. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.  Ann Intern Med. 1990;  112 397-406
• 129 Ji B, Truffot-Pernot C, Lacroix C et al.. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.  Am Rev Respir Dis. 1993;  148 1541-1546
• 130 Chapuis L, Ji B, Truffot-Pernot C, O'Brien R J, Raviglione M C, Grosset J H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.  Am J Respir Crit Care Med. 1994;  150 1355-1362
• 131 Jabes D, Della B C, Rossi R, Olliaro P. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.  Antimicrob Agents Chemother. 1994;  38 2346-2350
• 132 Miyazaki E, Chaisson R E, Bishai W R. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.  Antimicrob Agents Chemother. 1999;  43 2126-2130
• 133 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid.  Lancet. 1999;  353 1843-1847
• 134 Hu Y, Coates A R, Mitchison D A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis .  Antimicrob Agents Chemother. 2003;  47 653-657
• 135 Lounis N, Bentoucha A, Truffot-Pernot C et al.. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.  Antimicrob Agents Chemother. 2001;  45 3482-3486
• 136 Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.  Antimicrob Agents Chemother. 2003;  47 3117-3122
• 137 Perlman D C, El Sadr W M, Nelson E T et al.. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression.  Clin Infect Dis. 1997;  25 242-246
• 138 Snider Jr D E, Caras G J, Koplan J P. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy.  JAMA. 1986;  255 1579-1583
• 139 Khan K, Muennig P, Behta M, Zivin J G. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.  N Engl J Med. 2002;  347 1850-1859
• 140 McGregor M M, Olliaro P, Wolmarans L et al.. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.  Am J Respir Crit Care Med. 1996;  154 1462-1467
• 141 Franks A L, Binkin N J, Snider Jr D E, Rokaw W M, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients.  Public Health Rep. 1989;  104 151-155
• 142 Scheinhorn D J, Angelillo V A. Antituberculous therapy in pregnancy: risks to the fetus.  West J Med. 1977;  127 195-198
• 143 Snider Jr D E, Powell K E. Should women taking antituberculosis drugs breast-feed?.  Arch Intern Med. 1984;  144 589-590
• 144 Nolan C M, Elarth A M. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study.  Am Rev Respir Dis. 1988;  137 805-809
• 145 Livengood J R, Sigler T G, Foster L R, Bobst J G, Snider Jr D E. Isoniazid-resistant tuberculosis: a community outbreak and report of a rifampin prophylaxis failure.  JAMA. 1985;  253 2847-2849
• 146 Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato I M. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.  Clin Infect Dis. 1997;  24 1264-1265
• 147 Horn D L, Hewlett Jr D, Alfalla C, Peterson S, Opal S M. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis.  N Engl J Med. 1994;  330 1241
• 148 Lou H X, Shullo M A, McKaveney T P. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.  Pharmacotherapy. 2002;  22 701-704
• 149 Papastavros T, Dolovich L R, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.  CMAJ. 2002;  167 131-136